	US 11,655,453 B2
	Expansion of γδ T cells, compositions, and methods of use thereof
Richard Beatson, London (GB); Adrian Hayday, Kent (GB); Oliver Nussbaumer, London (GB); Richard Woolf, London (GB); Maria Luisa Iannitto, London (GB); and Natalie Mount, London (GB)
Assigned to King's College London, London (GB); and GammaDelta Therapeutics LTD, London (GB)
Appl. No. 16/610,398
Filed by King's College London, London (GB); and GammaDelta Therapeutics Limited, London (GB)
PCT Filed May 3, 2018, PCT No. PCT/EP2018/061413 § 371(c)(1), (2) Date Nov. 1, 2019, PCT Pub. No. WO2018/202808, PCT Pub. Date Nov. 8, 2018.
Claims priority of application No. 1707048 (GB), filed on May 3, 2017.
Prior Publication US 2021/0087528 A1, Mar. 25, 2021
Int. Cl. C12N 5/0783 (2010.01); A61K 35/17 (2015.01); A61K 45/06 (2006.01)

CPC C12N 5/0636 (2013.01) [A61K 35/17 (2013.01); A61K 45/06 (2013.01); C12N 2500/90 (2013.01); C12N 2501/21 (2013.01); C12N 2501/2301 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2309 (2013.01); C12N 2501/2312 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2318 (2013.01); C12N 2501/2321 (2013.01); C12N 2501/2333 (2013.01)]

17 Claims

1. A method of expanding γδ T cells, the method comprising the steps of:

(i) providing a population of γδ T cells obtained from a non-haematopoietic tissue; and

(ii) culturing the γδ T cells in the presence of:

(a) IL-2 or IL-9;

(b) IL-15; and

for at least 5 days in amounts effective to produce an expanded population of γδ T cells,

wherein the method further comprises, after step (i), separating the γδ T cells from non-haematopoietic cells to produce a separated population of γδ T cells, and step (ii) comprises culturing the γδ T cells in the absence of substantial stromal cell contact; and

wherein step (ii) comprises culturing the γδ T cells in the absence of exogenous TCR pathway agonists.